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pogers et al. (1) describe in this issue of the Journal the
argest report of functional capacity and quality of life to
ate in patients implanted with a continuous flow left
entricular assist device (LVAD). Patients were implanted
or 2 indications: bridge to transplant (BTT) (n  281) and
estination therapy (DT) (n  374). The authors conclude
hat both mortality reduction, improved quality of life
QOL), and functional capacity were achieved with a
ontinuous flow LVAD. Progressive improvement in sur-
ival has been observed over the last decade with the use of
continuous flow LVAD (2,3). The continuous flow
VAD is smaller, quieter, and more durable (3). Now
eported are improvements in QOL measures and func-
ional capacity that are unparalleled. Table 1 compares
unctional capacity and QOL measures in patients with
See page 1826
dvanced heart failure and shows the magnitude of change
ssociated with a continuous flow LVAD. It appears that
mproved survival with LVAD compared with medical
herapy was not enough to convince clinicians and patients
o accept LVAD therapy in the past. Now, however, the
ombination of improved survival and improved QOL has
esulted in wide acceptance of continuous flow LVAD and
apid growth in their use. The adoption of this therapy is
epicted by the rapid enrollment of the clinical trials and the
emand for the device in the continued access protocols
hich resulted in a cohort of 655 patients in this report.
igure 1 shows the growth in the axial flow pumps in the
ast 2 years.
It is important to acknowledge that the patients im-
lanted for the DT indication were deemed “ineligible for
ransplant.” The patients were elderly with advanced heart
ailure and no other options. We have reported a 6-month
ortality rate of almost 50% in patients treated with chronic
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Cardiology, Cleveland Clinic, Cleveland, Ohio. Dr.
tarling has had research sponsored by Thoratec and Medtronic, is on the publication(
ommittee of the INTERMACS Registry, is a committee member for HeartWare,
nd is a consultant for Medtronic.notropic therapy with advanced heart failure (4). Based on
he grave prognosis, we have recommended that inotropic-
ependent patients deemed not suitable for cardiac trans-
lantation be referred for LVAD or, alternatively, hospice if
ot candidates. Now there is a therapy (in addition to
ardiac transplantation) to offer patients that can reliably
xtend life and, importantly, improve QOL. For the first
ime, LVAD therapy has realized the expectation and
rowth that was anticipated over 20 years ago. This is timely
s the number of cardiac transplants per year has remained
nchanged for the past decade, yet the demand and patient
aiting list is large. Transplantation cannot meet the
emand, and the proliferation of LVAD is occurring as
echnology and outcomes have improved. The waiting list
ortality for cardiac transplantation is approximately 12%
5). A parallel observation has been the increased percentage
f patients supported with BTT LVAD prior to cardiac
ransplantation and is now 35% to 40% in the U.S.
mproved outcomes for BTT have led to improved physi-
ian confidence and a lower threshold to implant LVAD for
atients awaiting cardiac transplantation. A spot on the
ransplant waiting list is the opportunity to wait for an
rgan, but it does not treat the disease, and QOL remains
oor while waiting for an organ. Further, it has been shown
hat implanting LVAD for BTT in patients before a “crash
nd burn” status (INTERMACs level 1) results in better
urvival (6). So improved LVAD technology has resulted in
rowth in both the BTT and DT areas and is truly a
lifesaving” device for those waiting for transplant and those
neligible for cardiac transplant.
Finally, it is important to acknowledge that the QOL
easures used in this report assess the heart failure domain.
urrent-generation continuous flow LVADs still have per-
utaneous drive lines and external power supplies. Swim-
ing and bathing is prohibited, and physical activities are
estricted; the driveline must be immobilized and protected
rom trauma. Strokes, infections, and mechanical malfunc-
ions can be devastating. Although these limitations are
mproving with the continuous flow pumps compared with
he pulsatile pump, further refinements will result in im-
roved overall patient acceptance and QOL in all domains
3). The combination of improved quantity and quality of
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ailure with LVAD.
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Figure 1 Use of Approved LVADs in the U.S., 2006 to 2008
Over the past 2 years, a rapid growth in the use of continuous flow left ventric-
ular assist devices (LVADs) and a decline in pulsatile LVADs have been
observed. Adapted with permission from Kirklin et al. (6).
omparable Measures of QOL With Device Therapy: Post-InterventiTable 1 Comparable Measures of QOL With Device Therapy: Po
Parameter 2010 HeartMate II LVAD 2002 CR
MLHF (change in score) 42 18
KCCQ (change in score) 41 NA
6-min walk test, m 156 39
NYHA class 80% I, II 52% up 1 c
Abraham et al. (7); †Rose et al. (8).
CRT  cardiac resynchronization therapy; KCCQ  Kansas City Cardiomyopathy Questionnaire;
YHA  New York Heart Association.cf.org.
yEFERENCES
. Rogers JG, Aaronson KD, Boyle AJ, et al., for the HeartMate II
Investigators. Continuous flow left ventricular assist devices improves
functional capacity and quality of life of advanced heart failure patients.
J Am Coll Cardiol 2010;55:1826–34.
. Miller LW, Pagani FD, Russell SD, et al., HeartMate II Clinical
Investigators. Use of a continuous-flow device in patients awaiting heart
transplantation. N Engl J Med 2007;357:885–96.
. Slaughter MS, Rogers JG, Milano CA, et al., HeartMate II Investiga-
tors. Advanced heart failure treated with continuous-flow left ventric-
ular assist device. N Engl J Med 2009;361:2241–51.
. Gorodeski EZ, Chu EC, Reese JR, Shishehbor MH, Hsich E, Starling
RC. Prognosis on chronic dobutamine or milrinone infusions for stage
D heart failure. Circ Heart Fail 2009;2:320–4.
. Scientific Registry of Transplant Recipients, Funded by Health Re-
sources and Services Administration, Program and OPO Specific
Reports, Table 1 Waitlist Activity Summary Date 7/01/2008–06/30/
2009. Available at: http://www.ustransplant.org. Accessed March 4,
2010.
. Kirklin JK, Naftel DC, Kormos RL, et al. Second INTERMACS
annual report: more than 1,000 primary left ventricular assist device
implants. J Heart Lung Transplant 2010;29:1–10.
. Abraham WT, Fisher WG, Smith AL, et al., MIRACLE Study
Group. Multicenter InSync Randomized Clinical Evaluation. Cardiac
resynchronization in chronic heart failure. N Engl J Med 2002;346:
1845–53.
. Rose EA, Gelijns AC, Moskowitz AJ, et al., Randomized Evaluation of
Mechanical Assistance for the Treatment of Congestive Heart Failure
(REMATCH) Study Group. Long-term mechanical left ventricular
assistance for end-stage heart failure. N Engl J Med 200115;345:
1435–43.
ey Words: HeartMate II y ventricular assist devices y quality of life
angetervention Change
2001 HeartMate LVAD XVE† 2001 HeartMate Medical Arm
34 17
NA NA
NA NA
100% class II 100% class IV
left ventricular assist device; MLHF  Minnesota Living With Heart Failure; NA  not available;on Chst-In
T*
lassfunctional status y continuous flow.
